LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
LLY
902.74
-0.9%↓
UNH
596.8
+0.31%↑
NVO
131.05
+0.18%↑
JNJ
164.37
-0.29%↓
ABBV
193.18
+0.34%↑
Resumen
Variación precio
24h
Actual
Mínimo
82.94
Máximo
83.26
Recomendaciones | Compra Fuerte |
---|---|
Estimación a 12 meses | +6.27 upside |
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
82.46 / 87.21 Soporte y Resistencia
AstraZeneca PLC ADR Gráfico
Noticias Relacionadas
25 jul 2024, 09:17 UTC
AstraZeneca Raises Guidance After Results Beat Market Expectations -- Update
DJ
Leer
25 jul 2024, 06:48 UTC
AstraZeneca Raises Guidance After Revenue, Earnings Beat Market Expectations
DJ
Leer
12 jul 2024, 19:57 UTC
Instil Bio Shares Surge Following Rental Agreement with AstraZeneca
DJ
Leer
5 sept 2024, 13:00 UTC
China Detains AstraZeneca Employees Over Alleged Transport of Unapproved Drug -- WSJ
DJ
Leer
29 jul 2024, 10:30 UTC
Big Pharma Rallies and Moves Past Obesity -- Heard on the Street -- WSJ
DJ
Leer
25 jul 2024, 13:20 UTC
AstraZeneca Slides Despite Beating Quarterly Expectations And Hiking Its Outlook -- IBD
DJ
Leer
25 jul 2024, 09:21 UTC
AstraZeneca's Guidance Lift Is Conservative; Risks to Upside -- Market Talk
DJ
Leer
25 jul 2024, 07:05 UTC
AstraZeneca Guidance Raise Signals Portfolio Potential -- Market Talk
DJ
Leer
25 jul 2024, 06:06 UTC
AstraZeneca Increased Interim Dividend by 7c to $1.00
DJ
Leer
25 jul 2024, 06:04 UTC
AstraZeneca Had Seen Core EPS Grow by Low Double-Digit to Low Teens Percentage Range
DJ
Leer
25 jul 2024, 06:04 UTC
AstraZeneca Had Seen Total Revenue Grow by Low Double-Digit to Low Teens Percentage Range
DJ
Leer
25 jul 2024, 06:04 UTC
AstraZeneca Sees Core EPS Growth in 2024 by Mid Teens Percentage Range At Constant Currency
DJ
Leer
25 jul 2024, 06:04 UTC
AstraZeneca Sees Total Revenue Growth in 2024 by Mid Teens Percentage Range At Constant Currency
DJ
Leer
25 jul 2024, 06:03 UTC
AstraZeneca Raises 2024 View
DJ
Leer
25 jul 2024, 06:02 UTC
AstraZeneca 2Q Revenue Consensus Was $12.7B
DJ
Leer
25 jul 2024, 06:02 UTC
AstraZeneca 2Q Core EPS Consensus Was $1.95
DJ
Leer
25 jul 2024, 06:00 UTC
AstraZeneca PLC 2Q Adj EPS $1.98
DJ
Leer
25 jul 2024, 06:00 UTC
AstraZeneca PLC 2Q Pretax Pft $2.4B
DJ
Leer
25 jul 2024, 06:00 UTC
AstraZeneca PLC 2Q Rev $12.94B
DJ
Leer
25 jul 2024, 06:00 UTC
AstraZeneca PLC 2Q Oper Pft $2.75B
DJ
Leer
25 jul 2024, 06:00 UTC
AstraZeneca PLC 2Q Net Pft $1.93B
DJ
Leer
25 jul 2024, 06:00 UTC
AstraZeneca PLC 2Q EPS $1.24
DJ
Leer
15 jul 2024, 06:04 UTC
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
DJ
Leer
15 jul 2024, 06:04 UTC
AstraZeneca: Amolyt Pharma's Hldrs Eligible to Receive $250M On Achieving Specific Milestone
DJ
Leer
15 jul 2024, 06:02 UTC
AstraZeneca: Acquisition Includes $800M Upfront at Deal Closing
DJ
Leer
15 jul 2024, 06:02 UTC
AstraZeneca: Amolyt Pharma's Total Consideration of Up to $1.05B
DJ
Leer
15 jul 2024, 06:01 UTC
AstraZeneca: Acquisition Bolsters Alexion Rare Disease Late-Stage Pipeline
DJ
Leer
15 jul 2024, 06:00 UTC
AstraZeneca Completes Acquisition of Amolyt Pharma
DJ
Leer
15 jul 2024, 06:00 UTC
AstraZeneca PLC Acquisition of Amolyt Pharma completed
DJ
Leer
15 jul 2024, 06:00 UTC
AstraZeneca PLC Acquisition of Amolyt Pharma completed
DJ
Leer
Comparación entre iguales
Cambio de precio
AstraZeneca PLC ADR Esperado
Precio Objetivo
By TipRanks
Estimación a 12 meses
Media 88.26 USD 6.27%
Máximo 99 USD
Mínimo 74 USD
De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AstraZeneca PLC ADR Dist en los últimos 3 meses.
Consenso
By TipRanks
Compra Fuerte
6 ratings
5
Comprar
1
Mantener
0
Vender
De acuerdo con 6 analistas que ofrecen calificaciones bursátiles a para AstraZeneca PLC ADR Dist en los últimos 3 meses.
Puntuación técnica
By Trading Central
Corto Plazo
Very Strong Bearish Evidence
Recent bearish events outweigh bullish events.
Medio plazo
Bearish Evidence
Recent bearish events outweigh bullish events.
Largo Plazo
No Evidence
There are no events.